Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cleveland will test new prostate cancer drug
According to the trial protocol, enrollment of subjects of the main cohort may be initiated only if a limited number subjects of the first cohort experience adverse events.
According to the trial protocol, enrollment of subjects of the main cohort may be initiated only if a limited number subjects of the first cohort experience adverse events.
This new animal data demonstrate that oral administration of Guanilib significantly reduces gastrointestinal (GI) inflammation, and confirm earlier evidence of down-regulation of interleukin-17 (IL-17), IL-23, and tumor necrosis
Pegintron is administered once weekly at an individualized dose according to a patient’s weight and is the only pegylated interferon indicated in China for a 24 week treatment
The E1.7 million grant which was awarded to a consortium of nine leading universities and companies working in the field of influenza research, will finance preclinical and clinical
Adventrx is conducting preclinical pharmacokinetic testing of the drug, ANX-514, to compare this product candidate with the approved version of the product, marketed under the brand name Taxotere.
The study examined the effects of the Tibotec’s protease-inhibitor Prezista (darunavir), when combined with a low dose of the current antiretroviral ritonavir. The researchers checked for levels of
Previous studies have suggested that ibuprofen interferes with the effects of aspirin. In the study patients were taking either high dose, 400mg a day lumiracoxib, a type of
The study aims to demonstrate the dose, safety and immunogenicity of Intercell’s JE vaccine compared to a locally produced mouse-brain Japanese encephalitis vaccine. It is the first step
The preliminary results showed the drug was tested in patients with newly diagnosed multiple myeloma and combined with the steroid dexamethasone (Decadron) to treat the disease. Revlimid is
The application proposed the use of Genasense in combination with chemotherapy for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In a phase III trial